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Mutant Analysis in a Fission Yeast Model 
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Abstract 
 
Parkinson’s disease (PD) is the second most common 
neurodegenerative disease, affecting six million people 
worldwide. It results from the specific loss of substantia 
nigra dopaminergic neurons, which accumulate large 
filamentous structures called Lewy bodies composed 
mostly of one misfolded and aggregated protein called 
-synuclein. The aggregation and membrane 
phospholipid binding ability of -synuclein are both 
linked to cellular toxicity in familial and sporadic forms 
of PD, but their relative contributions are not resolved.  
This thesis utilized a Schizosaccharomyces pombe 
(fission yeast) model to get further insight into the 
nature of -synuclein toxicity in these two forms of PD 
and the data was comparatively evaluated with previous 
studies done in budding yeast. Three studies were 
conducted. First, for insight into familial PD, we tested 
the hypothesis that the newest mutant E46K -synuclein 
is toxic in fission yeast, but instead found it to be 
surprisingly slightly toxic. This lack of major toxicity 
correlated with extensive -synuclein aggregation and 
the lack of plasma membrane localization. In contrast, in 
budding yeast, E46K is known to be toxic, membrane 
localized, and not aggregated. Next, for insight into 
sporadic Parkinson’s disease, we first tested the 
hypothesis that alanine-76 in -synuclein as a major 
contributor to a-synuclein’s aggregation and found that 
an A76E mutant was indeed less aggregated in fission 
yeast. This finding supports past budding yeast work 
where A76E -synuclein is less plasma membrane 
localized. Lastly, we tested the hypothesis that post-
translational modifications in -synuclein contribute to 
its aggregation and to its known higher migration when 
run on protein gels. Surprisingly, phosphorylation-
deficient (S87A and S129A) and nitrosylation-deficient 
mutants (Y39F and Y125F) of -synuclein remained 
aggregated and their migration size on gels was 
unchanged. In contrast, these mutants are significantly 
toxic to budding yeast and maintain membrane 
localization. We suggest that fission yeast is more 
resistant than budding yeast to -synuclein toxicity 
possibly because membrane localization contributes 
toxicity, while aggregation protects. It is also possible 
that fission yeast more efficiently suppresses -
synuclein toxicity by thus far unknown mechanisms. 
Importantly, the mutants studied in both models 
demonstrate that -synuclein intrinsically regulates its 
ability to aggregate and bind membrane phospholipids, 
providing new insight into the toxicity seen in both 
sporadic and familial PD. 
 
Introduction 
 
Neurodegenerative Diseases 
________________________________________________ 
 
*This author wrote the paper as a Senior thesis under the direction of Dr. 
Shubhik DebBurman. 
Neurodegenerative diseases affect millions worldwide. 
These late onset progressive diseases, such as Alzheimer’s 
disease, Huntington’s disease, and Parkinson’s disease vary 
widely in symptoms. Despite symptom diversity, all 
neurodegenerative disease patient brains’ contain 
characteristic proteinaceous deposits. The location of the 
deposits, the morphology of the deposits, and the specific 
neuronal cell type affected, however, differ by disease 
(Caughey and Lansbury, 2003). The specific mechanisms of 
protein aggregation and their link to neuronal cell death in 
each disease are not yet conclusive.  Our interest lies in the 
molecular basis of Parkinson’s disease (PD). 
 
Parkinson’s disease 
Parkinson’s disease, first described by James Parkinson, is 
the second most common neurodegenerative disorder, 
affecting millions worldwide (Jain et al., 2005). This common 
and fatal neurodegenerative disease, characterized by 
postural instability, resting and bradykinesia, affects 1 in 50 
individuals over the age of 60 (Moghal et al, 1994). Sporadic 
and familial are the two forms Parkinson’s disease. The 
sporadic form of PD is the most common, making up 90-95% 
of PD cases. The remaining 5-10% of PD cases are familial 
and caused by a mutation in one of six genes (Dauer et al., 
2003). Both forms of PD are linked to the death of midbrain 
dopaminergic substantia nigra neurons, which accumulate a 
misfolded and aggregated protein -synuclein (Spillantini et 
al., 1997). As this specific cell death occurs, the release of 
the neurotransmitter dopamine decreases. The diminished 
amount of dopamine renders patients with a decreased 
ability to control and initiate movement, resulting in the 
clinical manifestations of PD (Figure 1; Dauer and 
Przedborski et al., 2003). My thesis will investigate the basis 
of cellular toxicity observed in both familial and sporadic PD.  
 
Basis of Familial PD 
Major breakthroughs occurred when the genes underlying 
familial PD were identified, as for first time a definitive cause 
of PD was revealed (Jain et al., 2005). Two autosomal-
dominant genes, (-synuclein and LRRK2) and three 
autosomal-recessive genes (parkin, DJ-1, and PINK1) have 
been associated with familial Parkinson’s disease (Jain et 
al., 2005).   
  Mutations in the parkin gene are associated with 
autosomal recessive, early-onset Parkinson’s disease 
(Kitada et al. 1998). This gene is a ubiquitin protein ligase 
(Shimura et al. 2000). The gene DJ-1, for which there are 
few known mutations, is the first gene discovery which did 
not lead to a direct implication of an abnormality of the 
proteasome-lysosome system. While the exact function of 
the DJ-1 protein is unknown, it may serve a role in protecting 
neurons against oxidative stress and mitochondrial damage 
(Bonifati et al., 2003).  The UCHL-1 gene may have a 
biological role in PD due to its ubiquitin ligase activity and 
may possibly act in the same pathway as parkin (Liu et al., 
2002). PINK I, the third autosomal-recessive PD gene 
discovered, functions as a serine/threonine kinase of the 
Ca2+/calmodulin family and contains a mitochondrial 
targeting motif in the N-terminus. PINK I is thought to protect 
cells against apoptosis by maintaining mitochondrial 
membrane potential during exposure to proteosome 
inhibitors (Valente, E.M. et al. 2004). The last two of the 
aforementioned genes, LRRK2 and UCHL-I, both lead to the 
 
 
Figure 1. Pathology of Parkinson’s disease: Both forms of 
Parkinson’s disease are characterized by very specific cell death. 
Upon autopsy, a severe loss of substantia nigra dopaminergic 
neurons in PD patients is observed. This neuronal loss results in a 
diminished release of the neurotransmitter dopamine, to the putamen 
and caudate nucleus, which in turn regulates the parts of the brain 
that control movement. The clinical manifestations of PD are a result 
this decrease in dopamine. 
 
autosomal-dependent form of PD. LRRK2 is part of a newly 
identified protein family referred to as ROCO. While the 
exact function of this protein is unknown, all other ROCO 
family proteins are involved in cytoskeletal rearrangement 
and may be implicated in apoptosis (Cohen et al., 1997; 
Abysahl et al., 2003).  
My study focuses on the first gene discovered to 
cause familial PD, -synuclein, because not only is it linked 
to both familial and sporadic PD, but all familial mutant 
genes described above eventually lead to -synuclein 
misfolding and aggregation. As described below, three point 
mutations in this gene result in single amino acid 
substitutions in the -synuclein protein: A30P, A53T, and 
E46K (Kruger et al., 1998; Polymeropoulos et al., 1997; 
Zarranz et al., 2004, respectively).  The examination of both 
wild-type and mutant versions of -synuclein is critical to the 
understanding of PD pathogenesis. 
 
Wild-type -synuclein is an aggregation prone protein 
This natively unfolded protein of 140 amino acids has three 
major regions (Kaplan et al., 2003). The first major region of 
this protein is an N-terminal amphipathic region consisting of 
amino acids 1-61. The central region consists of amino acids 
61-95 (Weinreb et al., 1996, Uversky et al., 2002). Deletion 
of the central region prevents -synuclein aggregation in vivo 
and in vitro, suggesting that this region is essential for 
aggregation of the protein (Giasson et al., 2000).   Finally, 
the third region, a highly acidic C-terminal region consists of 
amino acids 95-140 (Uversky et al., 2002). This C-terminal 
region may have an inhibitory role in the aggregation of -
synuclein, as C-terminally truncated forms of -synuclein are 
found to aggregate into filaments more readily than full-
length wild-type -synuclein (Baba et al., 1998). About 15% 
of Lewy bodies contain C-terminally truncated -synuclein 
(Baba et al., 1998). This protein of unknown function is 
located throughout the central nervous system and is 
abundant in neurons, especially in pre-synaptic terminals 
(Jakes, R.  et al., 1994) -synuclein may be involved in 
maintenance of vesicular pools (Jenson et al., 1998; 
Murphey et al., 2000), synaptic plasticity (George et al., 
1995, Abeliovich et al., 2000), phospholipid binding and lipid 
metabolism (Davidson et al., 1998; Eliezer et al., 2001; 
Sharon et al., 2001; Outiero and Lindquist, 2003), 
microtubule binding (Alim et al., 2004), and chaperone-like 
activity (Jenco et al., 1998, Engelender et al., 1999; 
Ostrerova et al., 1999). The aggregation and misfolding of 
this protein contributes to the formation of Lewy bodies, 
which are hallmarks of the disease.  
Many characteristics of A30P and A53T are now 
known and well-studied (Polymeropoulos et al., 1997; Kruger 
et al., 1998). In vitro, self-aggregation occurs in wild-type, 
A30 and A53T (Bisaglia et al., 2004; Bussell et al 2005; 
Davidson et al., 1997; Polymeropoulos et al., 1997; Kruger 
et al., 1998). Interestingly, the familial mutants vary in their 
abilities to bind lipids. Monomeric -synuclein binds to 
negatively charged phospholipid membranes and micelles in 
vitro, while A30P interferes with the -helical formation of the 
protein, rendering it unable to bind membranes (Bisaglia et 
al., 2004; Bussell et al 2005; Davidson et al., 1997). While 
both mutants undergo nucleated polymerization, A53T has a 
greater propensity to form large polymers, while A30P has a 
lesser propensity to form large polymers compared to wild-
type (Bussell et al. 2004; Jo et al., 2000). Moreover, the 
A53T mutation results in the accelerated formation of 
filaments compare to both wild-type an A30P -synuclein.  
 
Newly Discovered Mutant E46K 
In 2004, Zarranz et al. discovered a novel -synuclein 
mutation, E46K, which is linked to familial PD. Upon autopsy 
of the Spanish patients in which the mutation was found, 
severe atrophy of the substantia nigra was observed. Severe 
neuronal loss resulted, as well as the presence of numerous 
Lewy bodies that were immunoreactive to -synuclein. 
Several in vitro studies have examined the affects of this 
mutation on phospholipid binding and aggregative properties 
of the protein. Interestingly some evidence suggested that 
E46K increased the rate of fibrillization compared to A53T, 
while similar studies proposed that the rate of fibrillization for 
both mutants was similar (Greenbaum et al., 2005; Pandey 
et al., 2005; Choi et al., 2004). Interestingly, two types of 
aggregates have been found for E46K; These aggregates 
were larger than those found as a result of other mutations, 
such as A30P and A53T (Pandey et al., 2005). Furthermore, 
E46K fibrillar aggregates have a smaller diameter than that 
of the WT protein (Raaij et al., 2006). Little is known about 
how the previously described in vitro evidence may translate 
in living cells, tissues and organisms and what factors 
contribute to E46K dependent toxicity.  
 
Basis of Sporadic PD 
While Sporadic PD makes up for 90-95% of all PD, the exact 
causes are still unknown. Several hypotheses include 
oxidative stress, pesticides, proteasomal dysfunction, and 
mitochondrial dysfunction (Figure 2; Dauer and Przedborski, 
2003). In PD, Lewy body’s contain oxidatively modified -
synuclein, which results in an enhanced ability for -
synuclein to misfold and aggregate (Gaisson et al., 2000). 
The relationship between -synuclein  misfolding and 
oxidative stress is still unclear, however, oxidative stress 
may contribute to sporadic PD, as the presence of oxidative 
stress results in certain proteins forming a complex with 
aggregated -synuclein (Zhou et al., 2004).   Herbicides and 
pesticide, such as retonone, maneb, and paraquat may also 
play a role in sporadic PD as well. These agricultural agents 
have been shown to reproduce specific features of PD when 
administered to mice (Uversky et al., 2004).  Interestingly, 
occupational exposure to organic solvents may also 
correlate with induction of fibrillation prone, partially folded -
synuclein (Munishkina et al., 2003). Moreover, mitochondrial 
dysfunction may contribute to sporadic PD as inhibition of 
mitochondrial complex I by the environmental toxins 
paraquat, rotenone, and MPTP, result in cell damage (Abou-
Sleiman et al., 2006) and an increased death of 
dopaminergic neurons (Mizuno et al., 1989; Kweon et al., 
2004). Noteworthy is the invariable presence of -synuclein 
in Lewy bodies.  
 
Is Alanine-76 Relevant? 
Several in vitro studies have examined the contribution of 
alanine-76 to the aggregation of -synuclein. The deletion of 
a central stretch of -synuclein containing amino acids 61-95 
resulted in the prevention of -synuclein aggregation in 
these in vitro systems, suggesting that this region is crucial 
for the protein’s aggregation (Bodles et al., 2001). 
Interestingly, a hydrophobic, 12 amino acid stretch of -
synuclein, containing amino acids 70 to 82, was necessary 
and sufficient for filament assembly. The necessity of this 
specific region was determined through the deletion of the 
stretch, which results in the reduction of aggregation 
(Giasson et al., 2001). Notably, the insertion of a single 
charge in this stretch, resulting in the mutation A76E, leads 
to the decrease in aggregation of -synuclein (Gaisson et al., 
2001), suggesting that this alanine-76 is itself crucial to the 
aggregation of the protein. A mathematical model examining 
the effects of the substitution of a hydrophobic amino acid 
alanine to the hydrophilic amino acid glutamic acids also 
suggested the possibility of reduced aggregation (Chiti et al., 
2000). Whether A76E results in the inhibition of aggregation, 
changes toxicity or alters -synuclein’s membrane 
phospholipid affinity  in living cells and changes toxicity yet 
to be determined. 
 
Post-translational Modifications 
While the molecular mechanism of -synuclein aggregation 
remains unknown, post-translational modifications may 
contribute to -synuclein misfolding and aggregation. 
Several post-translational modifications can occur on -
synuclein, such as ubitiquination (Shimura et al., 2001), 
glycosylation (Shimura et al., 2001), nitrosylation (Takahashi 
et al., 2002) and phosphorylation (Okoshi et al., 2000; 
Fujiwara et al., 2002). For this thesis, only two of these, 
phosphorylation and nitrosylation, are the subject of my 
investigation. 
 
The Link between -synuclein Phosphorylation and PD 
As previously mentioned, Lewy bodies are the hallmarks of 
PD. Interestingly, in Lewy Bodies, -synuclein is selectively 
and extensively phosphorylated at serine-129 (Fujiwara et 
al., 2002). In vitro evidence suggests that additional 
phosphorylation of -synuclein occurs at serine-87, however, 
phosphorylation at this site occurs less efficiently then that of 
serine-129 (Okochi et al. 2000). Evidence is lacking as to the 
kinase responsible for the phosphorylation of serine-87, 
however, several kinases are implicated in phosphorylation 
of -synuclein at seirne-129. In vivo evidence suggests that 
Gprk2 (Chen and Feany, 2005) and casein kinase 1 and 2 
(Okochi et al., 2000) phosphorylate serine-129. There is 
conflicting evidence as to the relationship between 
phosphorylation, aggregation, and toxicity. One in vivo study 
suggests that phosphorylation of serine-129 enhances -
synuclein toxicity and blocking of this phosphorylation site 
increases aggregate formation (Chen and Feany, 2005). 
Interestingly, a rat model suggests that the blocking of 
phosphorylation of serine-129 not only leads to a decrease 
in aggregate formation, but also an increase in intracellular 
toxicity and an exacerbation of -synuclein induced nigral 
pathology (Gorbatyuk et al., 2008) 
 
 
 
Figure 2. Forms of Parkinson’s Disease: There are two forms of PD, sporadic and familial. Six genes are mutated in cases of PD. We focus on -
synuclein, to which three missense mutations can occur. Two of these mutations, A30P and A53T, are well characterized. Less is known about the 
novel mutation, E46K. There are several hypotheses as to the causes of sporadic PD, including pesticides, infections, and mitochondrial dysfunction. 
Two factors may contribute to sporadic PD, including Alanine-76 and post-translational mutations.  
The Link Between -Synuclein Nitrosylation and PD 
Pathogenesis  
A second post-translational modification that can occur to -
synuclein is nitrosylation. Nitrosylation is of interest as -
synuclein inclusions in PD brains are strongly labeled for 
antibodies that specifically detect nitrated synuclein in 
autopsied PD brains (Trojanowski et al., 1998; Duda et al., 
2000). -Synuclein is nitrated at several residues, including 
tyrosine-39, as well as tyrosine-125, 133, and 136 (Giasson 
et al., 2000) by compounds such as peroxynitrate (Duda et 
al., 2000). As a result of nitrosylation, several modifications 
can occur, including the change in conformation of the 
protein, which leads to increased protein aggregation. Most 
importantly, the nitration of -synuclein results in enhanced 
formation of SDS-insoluble, heat-stable high molecular mass 
aggregates in vitro (Souza et al., 2000), the diminished 
binding of -synuclein to lipid vesicles, and the increase in 
fibril formation (Hodara et al., 2004). Whether post-
translational mutations alter rate of -synuclein aggregation 
in living cells, and what consequences that has to cellular 
toxicity, is still not resolved.  
 
Yeast Models of PD 
Several models have been used in order to study of PD and 
more specifically, -synuclein. One of these models has 
been the mouse model (Caughey and Lansbury, 2003; 
Dauer and Przedborski., 2003). Transgenic mouse models 
reproduce many features of the disease.  Worms (Lasko, et 
al. 2003), flies (Feany and Bender, 2000) and yeast (Outiero 
and Lindquist, 2003) are also effective models for PD.  
 Budding Yeast Model: Saccharomyces cerevisiae 
serves as an effective model for the examination of 
neurodegenerative diseases, including PD, prion diseases 
(Ma and Lindquist, 1999), Huntington’s disease (Krobitsch 
and Lindquist, 2000; Muchowski et al. 2002), and 
amyotrophic lateral sclerosis (Kunst et al. 1997). Importantly, 
budding yeast shares with humans a high conservation of 
protein quality control pathways and of protein folding. 
Several investigations have concentrated on the study of 
familial mutants in yeast. In fact, four budding yeast models 
for studying -synuclein properties found that wild-type and 
A53T mutant -synuclein are plasma membrane associated 
proteins that can aggregate within cells, whereas the A30P 
mutant neither localizes to the plasma membrane nor 
aggregates (Outiero and Lindquist, 2003; Zabrocki et al., 
2005; Dixon et al., 2005). However, the support for -
synuclein toxicity to budding yeast is varied: two models 
demonstrate -synuclein aggregation itself is toxic to yeast 
(Outiero and Lindquist, 2003; Dixon et al., 2005), while two 
others suggest that -synuclein-dependent toxicity requires 
an additional chemical or genetic insult, such as proteasomal 
inhibition and oxidative stress (Zabrocki et al., 2005). Our lab 
has also developed a budding yeast model for the 
examination of -synuclein misfolding and aggregation. In 
our budding yeast model, wild-type and A53T display plasma 
membrane localization, supporting the protein’s known in 
vitro binding abilities (Sharma et al., 2006). In contrast, A30P 
localizes primarily throughout the cytoplasm, whereas the 
A30P/A53T mutant displays both phenotypes. In this model, 
toxicity is enhanced in cells exposed to an increased amount 
of oxidative stress or in cells with proteasomal impairment, 
supporting several in vitro studies (Sharma et al., 2006).  
Using the budding yeast model, our lab has 
recently shown that E46K confers toxicity to budding yeast 
(Sara Herrera Thesis, 2005; Michael White Thesis, 2007). 
These studies demonstrate that E46K toxicity is ploidy-
specific and strain-specific. Furthermore, E46K -synuclein 
expressing cells have extensive plasma membrane 
localization and show reduced protein expression when 
compared to wild-type -synuclein. Like E46K, A76E and 
four post-translational modification mutants (S129A, S87A, 
Y39A, Y125F) have been examined and result in the toxicity 
of budding yeast cells (Michael Zorniak Thesis, 2007; Sara 
Herrera Thesis, 2005). Interestingly, plasma membrane 
localization decreases for A76E suggesting that alanine-76 
facilitates membrane phospholipids association (Michael 
Zorniak Thesis, 2007). All four post-translational modification 
mutants, however, maintain primarily membrane localization. 
Thus, our budding yeast model points to membrane 
localization as a link to -synuclein toxicity.  
Fission Yeast Model: Our lab has also developed 
and published a fission yeast model for PD that supports the 
nucleation polymerization theory for -synuclein degradation 
(Brandis et al., 2006). Schizosaccharomyces pombe (fission 
yeast), like budding yeast, also serves as a powerful model 
organism in cell biology, as it provides insight into eukaryotic 
cell cycle (Fantes and Beggs, 2000), DNA repair and 
recombination (Davis and Smith, 2001), and checkpoint 
controls needed for stability (Humphrey, 2000). Like budding 
yeast, fission yeast shares with humans a high conservation 
of protein folding and protein quality control pathways (Wood 
et al., 2002). In fission yeast, -synuclein-A30P and 
combination mutant A30P/A53T are cytoplasmically diffuse, 
while wild-type -synuclein and A53T form prominent 
inclusions. This inclusion formation occurs in a time and 
concentration-dependent manner (Brandis et al., 2006). 
A53T forms aggregates at a faster rate than WT--synuclein.  
Most interesting, however, are the lack of -synuclein 
plasma membrane localization and the lack of -synuclein-
dependent toxicity. 
Both fission and budding yeast serve as effective 
models for examining -synuclein properties. First, yeast is 
inexpensive. Secondly, they grow quickly, which allows for 
faster experimentation than other models. Importantly, their 
entire genome has been sequenced, which allows us to 
make genetic mutations and examine the molecular basis of 
the disease. Lastly, yeast make, fold and degrade proteins 
similarly to humans. Since this disease is one involving 
protein misfolding, this property is important.  
While a majority of work in our lab has previously 
focused on the characterization of -synuclein in a budding 
yeast model, the goal of my thesis was to further examine 
how E46K, A76E, and the four post-translational modification 
mutants (S129A, S87A, Y39F, Y125F) affect the intrinsic 
aggregation and phospholipid binding properties of -
synuclein in a fission yeast model and compare my data with 
those obtained from budding yeast. 
 
Hypotheses and Aims 
I conducted three related studies to test the following 
hypotheses. For each hypothesis, I evaluated -synuclein 
mutant expression through Western blot analysis, toxicity 
through OD600 growth curves and spotting assays, and 
localization/aggregation through live cell GFP microscopy in 
fission yeast.  
 Hypothesis I: To gain insight into familial PD, I 
tested the hypothesis that E46K mutant -synuclein is toxic 
to live fission yeast cells and displays both plasma 
membrane binding and aggregation. I predicted that E46K 
would aggregate more than wild-type -synuclein. My 
findings are detailed in Chapter I. 
 Hypothesis II: To gain insight into 
sporadic PD, I hypothesized that alanine-76 contributes to -
synuclein aggregation. I predicted that the A76E mutation 
would decrease aggregate formation due to its decreased 
hydrophobicity. My findings are detailed in Chapter II. *Note: 
The following three figures (Figures 3-5) summarize our lab’s 
budding yeast findings and illustrate the properties that are 
yet to be examined in fission yeast.  
-synuclein  Properties in Fission Yeast 
 
 WT A30P A53T E46K 
Diffuse - + - ? 
Aggregate + - + ? 
Lipid Binding  - - - ? 
Toxicity - - - ? 
 
B. E46K Properties in Budding Yeast 
 
E46K Budding Yeast 
Diffuse 
 
- 
Aggregate - 
Lipid Binding  + 
Toxicity + 
 
 
 
Figure 3. Known E46K Properties in Yeast Models.  
A. Characterization of several -synuclein mutants in a fission yeast model showed that A30P displayed diffuse localization, whereas aggregation of -
synuclein was observed in A53T, similarly to WT -synuclein.E46K properties in fission yeast remain to be examined.   
B. In budding yeast, E46K mutant -synuclein confers toxicity, display membrane localization.  
 
 
 
 
 
Figure 4.  Mode of Alanine-76 Action.  
A. -Synuclein is a protein of 140 amino acids with three major regions. The central hydrophobic region of the protein is thought to be critical to the 
aggregation of the protein. 
B.  Alanine-76 may contribute to the aggregation of -synuclein, as it is a hydrophobic amino acid, which is likely to polymerize. The A76E mutation 
may increase the solubility of the protein due to the hydrophilic nature of glutamic acid. 
C.  In budding yeast, A76E confers slight toxicity, results in a lack of aggregation and reduction in membrane localization.   
A. Phosphorylation and Nitrosylation on -Synuclein 
 
Site Relevance to PD Citation 
S87 
S87 is phosphorylated in vitro. Evidence on effect of ser-87 
phosphorylation on fibril formation is lacking. 
Okochi et al., 2000 
S129 Phosphorylation of ser-129 increases fibril formation in vitro. Fujiwara et al., 2002 
Y39 
Nitration of Y39 results in a diminished binding to lipid vesicles and 
in the increase of fibril formation 
Hodara et al., 2004 
Y125 
Lack of nitration at this site results in the reduction of dimerization 
of -synuclein Takahashi et al., 2002 
 
B. Post-Translational Effects on -Synuclein in Budding Yeast 
 
Mutation Toxicity Lipid Binding Aggregation 
S87A + + - 
S129A + + - 
Y39F + + - 
Y125F + + - 
 
Figure 5.  Effects of Post-translational Modification Mutants on -Synuclein.  
A. Several studies have examined the phosphorylation and nitrosylation of -synuclein. The effect of phosphorylation have been examined in vitro. In 
vivo examination of the post-translational modifications’ is lacking and the effects on these mutations on toxicity and aggregation of -synuclein are yet 
to be determined.   
B. Post-translational mutations were examined in a budding yeast model. All four modification mutants showed toxicity as well as localization to the 
plasma membrane. Post-translationally modified -synuclein displayed lack of aggregation. 
 
Methods 
 
Study Site: DebBurman Laboratory, Lake Forest College, 
Lake Forest, Illinois. 
 
Vectors:  All forms of -synuclein and GFP were expressed 
using the pNMT1-TOPO DNA vector (Invitrogen).  
 
-Synuclein: C-terminally GFP tagged human wild-type, 
A30P, A53T, E46K, A76E, A30P/E46K, A53T/E46K, 
A30P/A53T/E46K, S89A, S129A, Y39F, and Y125F were 
used.  
 
Expression of -synuclein: Fission yeast cells were grown in 
PDM-leucine media. This media allows for the growth of the 
fission yeast without allowing for the expression of -
synuclein and GFP.  A thiamine repressible within our vector 
was used in order to manipulate expression of the proteins 
-synuclein and GFP. Cells are first grown overnight. These 
are then centrifuged at 2500 rpm at 4˚C. They are 
subsequently washed with water twice, after which they are 
inoculated in EMM-thiamine liquid media.  This media allows 
for the growth of fission yeast cells as well as the expression 
-synuclein and GFP.  
 
Site-Directed Mutagenesis: The A30P/E46K, A53T/E46K 
and A30P/A53T.E46K combination mutants were made 
using Gene Taylor Site-Directed Mutagenesis Systems and 
Taq High Fidelity polymerase (Invitrogen; Figure 3).  C-
terminally GFP-tagged A30P, A53T, and A30P/A53T mutant 
-synuclein constructs were used for this site-directed 
mutagenesis. The DNA mutagenesis product was 
transformed into One Shot Max Efficiency Dh5-T1 
Competent Cells. Yeast colonies were then mini-prepped 
(Qiagen Mini-prep Kit) in order to isolate the mutated 
plasmid. The mutation of -synuclein was confirmed by 
sending DNA to the University of Chicago Cancer Research 
Center DNA Sequencing Facility.  
 
Transformation of Yeast Strains: WT-GFP and A76E TCP1 
fission yeast cells were previously transformed by Michael 
Zorniak 07’.  E46K fission yeast and all post-translation 
mutants were transformed by Isaac Holmes (Table 1).  
 
Bacterial Whole Cell Polymerase Chain Reaction (PCR): 
Amplification of bacterial DNA was achieved using Bacterial 
Whole Cell PCR. Each reaction is set up in a 0.2 ml 
microcentrifuge tube. The following was added to each 
reaction: 7 µL H20, 2.5 µl Forward primer, 2.5 µl reverse 
primer, 12.5 µl Master mix (MgCl2, Buffer, Taq DNA 
polymerase, dNTP) and 0.5 µl of bacterial cells (Qiagen 
mini-prep product). A similar reaction is set up as a positive 
control with control plasmid. The PCR program was as 
follows: 95˚C 30 sec., 55˚C 30 sec., 72˚C 30 sec. (this cycle 
is repeated 29 times), 72 ˚C 30 min., 4˚C indefinitely.   
 
Western Analysis: Cells were grown in PDM-leucine at 30˚C 
over night. These cells were centrifuged for 5 minutes at 4˚C 
and subsequently washed twice with water. The washed 
pellet was then inoculated in EMM-thiamine media, which 
allows for the expression of -synuclein. Cells were counted 
and a cell density of 2.5X 10
7
 was isolated 24 hours post-
induction. The isolation process required the centrifugation 
of the cells in a countertop centrifuge at (34,000) rpm. Cells 
were lysed using electrophoresis solubilizing buffer (ESB) 
and small glass beads. 10 µL of each lysate and See Blue 
mass ladder (Invitrogen) were loaded into Tris-glycine gels 
(Invitrogen). Chambers of the gel box were filled with 1X 
running buffer (29.0 g Tris-base, 144.0 g Glycine, 500 mL, 
SDS, 1L H2O at pH 8.7). The lysates were electrophoresed 
at ~130 V. Protein transfer to PVDF membranes was 
performed using Semi-Dry Transfer Apparatus (Biorad), 
methanol, water, and 1X transfer buffer (18.3g Tris-base, 
Construct Expression Vector  Strain 
WT -synuclein-GFP  pNMT1 TCP1 
Parent Plasmid -synuclein-GFP  pNMT1 TCP1 
A30P -synuclein-GFP  pNMT1 TCP1 
A53T -synuclein-GFP  pNMT1 TCP1 
E46K -synuclein-GFP  pNMT1 TCP1 
A30P/E46K -synuclein-GFP  pNMT1 TCP1 
A53T/E46K -synuclein-GFP  pNMT1 TCP1 
A30P/A53T/E46K -synuclein-GFP  pNMT1 TCP1 
A76E -synuclein-GFP  pNMT1 TCP1 
S89A -synuclein-GFP  pNMT1 TCP1 
S129A -synuclein-GFP  pNMT1 TCP1 
Y39F  -synuclein-GFP  pNMT1 TCP1 
Y125F -synuclein-GFP  pNMT1 TCP1 
 Parent plasmid- -synuclein-GFP pNMT1 Sp 
 WT -synuclein-GFP pNMT1 Sp 
 E46K -synuclein-GFP pNMT1 Sp 
 
Table 1.  Transformed Schizosaccharomyces pombe Strains: All -synuclein constructs were previously transformed into S. 
pombe. Newly synthesized A30P/E46K, A53T/E46K, and A30P/A53T/E46K combination mutants were transformed into S. pombe. 
The DNA construct is presented in the left column, the expression vector is presented in the center column and the DNA construct is 
presented in the right column.  
 
90.0 g Glycine, 500 mL  H2O,  at pH 8.3).  Blocking was 
extended to three hours and blotting was performed using 
Anti-V5/Alkaline phosphatase, -actin mouse monoclonal 
antibody and Anti-mouse secondary antibody (Invitrogen). 
All washes with antibody wash performed during the blotting 
process were extended from 5 minutes to 10 minutes. 
Membrane allowed to air dry and then photographed 
 
Growth Curve Analysis: Cell density was assessed via an 
optical density assay at a 600nm wavelength. Cells were 
grown overnight in 10 mL of PDM-leucine media at 30˚C. 
The 10 ML cell culture is transferred to a centrifuge tube and 
centrifuged at 1500 xg for 5 minutes at 4˚C and 
subsequently washed with water. Cells were re-suspended 
in 10 mL of DI H2O and counted using a hemocytometer to 
determine cell density. A cell culture of 2.0x 10
7 
was 
inoculated in 35 mL of EMM-leucine and EMM+leucine 
media and grown in a shaken incubator at 30˚C for 48 hours. 
Two 1 mL cultures were removed from each flask at 0, 3, 6, 
18, 24, 36, and 48 hours and placed in two cuvettes for 
duplicate readings. Readings were made using the Hitachi 
U-2000 Spectrometer at a 600nm wavelength.  
 
Cell Spotting/ Growth Rate Analysis: Cells were grown in 10 
mL of PDM-Leucine liquid media overnight at 30˚C. Each 10 
ml sample was centrifuged at 1500xg and subsequently 
washed with 5 mL of sterile H20. The resulting pellet was re-
suspended in 10 mL of DI H20 and counted.  A 2.7x10
7
 
cell/mL cell culture was removed from the 10 mL culture, 
centrifuged and water was removed. The resulting pellet was 
re-suspended in 1 mL of H20. A 100 µl sample of the 
2.7x107 cells/mL were pipetted into the first well of a 96-well 
microliter plate. The cultures were 5-fold serially diluted 
across the plate. 2 µl of each dilution was plated onto 
EMM+thiamine and EMM-thiamine plate. Once all the 
samples were plated, the plates were stored in a 30˚C 
incubator for ~48 hours or until colonies were visible. Plates 
were then photograph and stored at 4˚C.  
 
Time-Course Microscopy: Time-course microscopy was 
used in order to analyze the localization of wild-type and 
mutant -synuclein during expression in fission yeast cells. 
Images were taken using a Nikon TE-2000-U fluorescent 
microscope and Metamorph® 6.0 software. One milliliter of 
each sample (WT-GFP, A76E-GFP, E46K-GFP, S89A-GFP, 
S129-GFP, Y39F-GFP, and Y125F-GFP) was removed from 
an inoculated culture in EMM-thiamine media. Each sample 
was centrifuged in a tabletop centrifuge at (34000 rpm) for 1 
minute after which about ~80% of the media was poured off. 
Ten µl of each culture was pipetted onto a glass slide and 
covered with a cover slip. Two images were obtained for 
each culture, one being a differential interference contrast 
(DIC) and the second being a fluorescence image. At each 
time point, 15 DIC and 15 fluorescence images were taken 
to ensure that at least 750 ells were imaged.  
 
Results 
 
E46K Is Slightly to Fission Yeast Strain TCP1 
Our first goal was to characterize toxicity familial mutant 
E46K-GFP -synuclein in fission yeast. First, optical density 
analysis at 600 nm (OD600) was performed in order to 
analyze E46K effects on cell growth. As was previously 
reported (Brandis et al. 2006), parent vector, GFP alone, and 
wildtype -synuclein expressing cells were not toxic to 
fission yeast (Figure 6A). Despite significant differences (p= 
.013251), we consider E46K to be minimally toxic (Figure 
6A). Serial spotting was used as a second method of 
examining cellular toxicity. No difference in colony survival 
was observed between wild-type and E46K--synuclein, and 
this survival was similar to that of cells containing parent 
vector expressing GFP alone (Figure 6B). Therefore, 
together both assays revealed that E46K is minimally toxic to 
fission yeast cells.  
 
Similar Expression of E46K and Wildtype -Synuclein in 
TCP1 
To determine if E46K resulted in -synuclein accumulation or 
in the presence of higher order aggregated protein, Western 
Blot analysis of E46K at 24 hours post–induction of -
synuclein in TCP1 showed no difference in expression 
between wild-type and E46K expressing cells in TCP1. 
Furthermore, we see the presence of higher molecular 
weight aggregates (Figure 6C). 
 
 
E46K -Synuclein Aggregates Similarly to Wild-Type in 
TCP1 
To evaluate if E46K aggregates and/or localizes to the 
plasma membrane, live cell GFP microscopy was 
conducted. As previously reported (Brandis et al., 2006), 
wildtype and A53T formed distinct cytoplasmic aggregates, 

 
 
 
 
Figure 6. Characterization of E46K -synuclein  in Fission Yeast Strain TCP1 
A. Growth Curve Analysis: Growth Curve during 48 hours of expression for Parent plasmid (blue line), GFP ( red line), WT-GFP (yellow line) and 
E46K (green line). Culture density indicated by absorbance (nm) on the y-axis and time (hrs) after -synuclein  induction. Data points 
representative of mean of three trials. Standard Error of the Mean (S.E.M.) bars given for each for each data point. Slight difference in growth 
observed between WT-GFP and E46K in fission yeast in -synuclein inducing media. (n=3, p=.013251) 
B. Cell Spotting: TCP1 cells were serially diluted and spotted on -synuclein inducing (EMM-thiamine) and non-inducing (EMM+thiamine) media to 
evaluate effect of -synuclein expression on cell growth. Media plate with -synuclein  repressing solid media EMM+thiamine to the left and 
media plate with -synuclein  inducing solid media EMM-thiamine to the right. No difference in growth observed between WT-GFP and E46K on 
-synuclein  inducing or non-inducing media (n=3). 
C. Western Analysis: Cells were grown in -synuclein inducing (EMM-thiamine) and non-inducing (EMM+thiamine) media for 24 hours. At 24 hours, 
western analysis was performed. Blots were probed with an anti-V5 antibody, which binds exclusively to the V5 tag on -synuclein.  -synuclein 
bands are visible at ~54 kDa. No difference in expression observed between E46K and WT.  
D. Live Cell Microscopy:  Wild-type (Brandis et al., 2006) and E46K fission yeast cell constructs were C-terminally tagged with GFP. Fluorescent 
images of wild-type E46K -synuclein  fission yeast taken over 36-hour time course at 1000X magnification. Images taken at 6, 12, 18,24 and 36 
hours post-induction.  
E. Quantification of Phenotypes: A total of 750 cells were imaged for quantification. At each time point, cells were quantified as having one (blue), 
two (yellow) or three plus (maroon) inclusions. Percentage of cells exhibiting each phenotype plotted. Percentage of aggregates increases in a 
time-dependent manner. 
 
 
 
Figure 7. Characterization of E46K -synuclein  in Fission Yeast Strain Sph- 
A. Growth Curve Analysis: Growth Curve during 48 hours of expression for Parent plasmid (blue line), WT-GFP (pink line), and E46K (yellow line). 
Culture density indicated by absorbance (nm) on the y-axis and time (hrs) after -synuclein  induction. Data points represent the mean of three 
trials. Standard Error of the Mean (S.E.M.) bars given for each for each data point. No difference in growth observed between WT-GFP and E46K 
in fission yeast strain Sp in -synuclein inducing media. (n=3; p=.36058) 
B. Cell Spotting: PP, GFP, WT and E46K Sph- cells were serially diluted and spotted on -synuclein inducing (EMM-thiamine) and non-inducing 
(EMM+thiamine) media to evaluate effect of -synuclein expression on cell growth. Media plate with -synuclein  repressing solid media 
EMM+thiamine to the left and media plate with -synuclein  inducing solid media EMM-thiamine to the right. No difference in growth observed 
between WT-GFP and E46K on -synuclein  inducing or non-inducing media (n=3). 
C. Western Analysis: Cells were grown in -synuclein inducing (EMM-thiamine) media for 24 hours. At 24 hours, Western analysis was performed. 
Blots were probed with an anti-V5 antibody, which binds exclusively to the V5 tag on -synuclein.  -synuclein bands are visible at ~54 kDa.  
D. Live Cell Microscopy:  E46K fission yeast cell constructs C-terminally tagged with GFP. Fluorescent images of E46K -synuclein  fission yeast 
taken over 36 hour time course at 1000X magnification. Images taken at 18 hours post-induction.  
E. Quantification of Phenotypes: A total of 750 cells were imaged  for quantification. At each time point, cells were quantified as having either one 
(blue), two (yellow), or three plus (maroon) inclusions. Percentage of cells exhibiting each phenotype are plotted. Percentage of aggregates 
increases in a time-dependent manner. 
while A30P is cytoplasmically diffuse (Figure 6D). Similar to 
wild-type and A53T, E46K also formed distinct aggregates in 
TCP1, ranging from 1-5 per cell. Because A53T aggregates 
faster and earlier than the wildtype form in fission yeast 
(Brandis et al. 2006), we asked if E46K did the same. Over a 
36-hour time course, we observed no difference in the timing 
or extent of -synuclein aggregation between wild-type and 
E46K (Figure 6E).  Notably, at no time during this time 
course, does E46K localize to the plasma membrane (Figure 
6E), again behaving similarly to wild-type and A53T, which 
do not localize to fission yeast plasma membrane either 
(Figure 6D; and Brandis et al. 2006). 
 
Aggregation and lack of E46K Toxicity is Not Strain Specific 
Finally, to assess whether the lack of major E46K toxicity 
was specific to TCP1 or if this property was universal to 
multiple fission yeast strains, we repeated the TCP1 assays 
in a second fission yeast strain, Sp. Both the growth curve 
and serial spotting on plates revealed that E46K was not 
toxic in Sp (Figures 7A and B; p=.36058). Furthermore, no 
difference in expression was observed between wild-type 
and E46K expressing cells in Sp. Also absent was the 
presence of higher molecular weight aggregates.  Similar to 
observations in TCP1, E46K formed distinct cytoplasmic 
aggregates (Figure 7D), resembling wildtype and A53T 
aggregation cells previously reported for Sp1 (Brandis et al., 
2006). Interestingly, live cell microscopy revealed a second 
intracellular phenotype for -synuclein, common to both 
wildtype and E46K forms; because we have not been able to 
confirm the identity of these internal structures yet, we have 
for now scored it as “other” (Figure 7E).  
 
Discussion 
 
This study represents the first assessment of E46K -
synuclein  in a fission yeast model and is one of the first 
studies of E46K in any living cell. Very little is still known 
about E46K properties in cells and tissues and nearly all 
published work describes its properties in in vitro systems. 
Here, we report that E46K aggregates extensively in live 
cells without plasma membrane association and does not 
confer major toxicity to fission yeast. As will be discussed 
below, these fission yeast findings significantly differ from 
E46K -synuclein  characteristics in budding yeast. 
Therefore, in addition to giving new insight into the nature of 
-synuclein  toxicity, our study stresses the importance of 
using both fission and budding yeast models when 
evaluating protein misfolding and toxicity in yeast systems.  
 
E46K Promotes Extensive Aggregation in Fission Yeast  
As hypothesized, E46K aggregates extensively in our fission 
yeast model. This aggregation is reminiscent of the 
characteristic aggregation seen in Lewy bodies in human PD 
brains (Choi et al., 2004).  Therefore, fission yeast serves as 
a good model for examining E46K. Furthermore, this live cell 
aggregation supports in vitro data about E46K, which 
demonstrate that E46K increases the rate of fibrillization of 
-synuclein (Greenbaum et al., 2005; Pandey et al., 2005; 
Choi et al., 2004).  
In fission yeast, E46K aggregation resembles that 
of A53T and WT in its propensity to aggregate and this 
aggregation is notably different from A30P’s cytoplasmic 
localization (Dixon et al. 2005; Outiero and Lindquist, 2003; 
Zabrocki et al. 2005). Our fission yeast model findings that 
A53T and WT have a high propensity to aggregate are 
comparable to those found in in vitro studies. Furthermore, 
our findings that familial mutant A53T aggregates at a faster 
rate than WT are also comparable to in vitro studies (Bussell 
et al. 2004; Jo et al., 2000). Surprisingly, E46K does not 
aggregate faster than wild-type. While WT and A53T 
mutations promote the accumulation of intermediate 
aggregate, or protofibrils, E46K does not, suggesting that the 
extent of aggregation may be critical for disease and toxicity 
linked to disease (Greenbaum et al., 2005).  
 
E46K Surprisingly Results in Lack of Membrane Association 
The phospholipid binding abilities of E46K have been 
thoroughly examined in vitro and suggest that E46K 
increases -synuclein ’s phospholipid binding abilities (Choi 
et al., 2004). This observation may explain E46K mutant -
synuclein’s membrane binding affinity and the modest 
intracellular aggregation in budding yeast. (White, 2007; See 
Appendix A, pg 60). While we had hypothesized that E46K 
would result in membrane binding, E46K in fission yeast 
lacks membrane binding. Differences in the membrane 
binding properties between fission and budding yeast may 
be attributable to differences within the phospholipid 
membranes of the yeast themselves. It is a possibility that 
there may be reduced or altered plasma membrane 
phospholipid composition, or differences in membrane 
proteins with which -synuclein interacts, leading to the lack 
of membrane association (Brandis el al., 2006).  
 
E46K Confers Slight Toxicity in One Strain of Fission yeast 
The most notable finding is the unexpected lack of major 
E46K dependant toxicity. A major hypothesis in the field of 
neurodegenerative diseases had been that aggregation was 
key to cellular toxicity (Geodert et al., 2001). In recent times, 
this position has changed as aggregation is now thought to 
be protective or minimally harmless. One possibility to 
explain the major E46K dependent toxicity is the extent of 
aggregation in E46K -synuclein . Perhaps, aggregation 
happens to fast in fission yeast, and less intermediates form. 
Possibly, intermediate aggregates are the causative factor of 
toxicity, as also suggested by the extensive aggregation and 
lack of toxicity seen in WT and A53T (Brandis et al., 2006). 
In our yeast models, most cells displaying predominant 
membrane localization also exhibit -synuclein-dependent 
toxicity (Brandis et al., 2006; Sharma et al., 2006), therefore, 
a second reason that E46K may not result in major toxicity 
may be the lack of membrane association seen in E46K -
synuclein. Lastly, the lack of major toxicity in fission yeast 
may be due to the difference in the genomes of the yeast 
themselves. The fission yeast genome may provide a 
protective response that is not observed in budding yeast. 
While these possible protective mechanisms are not known, 
uncovering these mechanisms may help us better 
understand the disease.  
 
Chapter 2: Characterization of A76E -synuclein in 
Fission Yeast 
 
Results  
 
A76E is Less Aggregated 
First, we evaluated whether the mutation A76E reduced -
synuclein aggregation in fission yeast, live cell microscopy 
was conducted. As we had hypothesized, A76E reduced -
synuclein aggregation, compared to wild-type -synuclein 
(Figure 8A). Quantification of this microscopy confirmed that 
wild-type -synuclein formed distinct intracellular aggregates 
in most cells, as previously reported in Brandis et al. 2006, 
while A76E expressing cells demonstrated a significant shift 
of -synuclein localization to the cytoplasm, with many cells 
now showing a combined cytoplasmically 
diffuse/aggregation phenotype (Figure 8B). Interestingly, no 
-synuclein membrane localization was observed with A76E, 
as would be predicted for this more hydrophilic mutant 
(Figure 8A,B).  
 
Expression of -Synuclein Unchanged by A76E  
Next, to evaluate if A76E affected the expression of -
synuclein, Western blot analysis of A76E cells was 
performed at 24 hours post-induction of -synuclein. A76E 
cells and wild-type expressing cells showed no difference in 
expression, despite the reduction in aggregation (Figure 8C). 
 
 
 
 
 
Figure 8. Characterization of A76E -synuclein  in Fission Yeast 
A. Live Cell Microscopy:  A76E fission yeast cell constructs C-terminally tagged with GFP. Fluorescent images of A76E -synuclein fission yeast taken 
over 36 hour time course at 1000X magnification. Images taken at 12 and 24 hours post-induction.  
B. Quantification of Phenotypes: A total of 750 cells were imaged  for quantification. At each time point, cells were quantified as having either diffuse 
fluorescence (maroon), or aggregate (blue). Percentage of cells exhibiting each phenotype at 24 and 48 hours plotted. A76E reduces aggregation of -
synuclein  in fission yeast.  
C. Western Analysis: Cells were grown in -synuclein inducing (EMM-thiamine) and non-inducing (EMM+thiamine) media for 24 hours. At 24 hours, 
western analysis was performed. Blots were probed with an anti-V5 antibody, which binds exclusively to the V5 tag on -synuclein.  -synuclein bands 
are visible at ~52 kDa. There is no difference in expression between A76E and WT.  
D. Growth Curve Analysis: Growth Curve during 48 hours of expression for parent plasmid (dark blue), GFP (pink), WT-GFP (yellow line) and A76E ( 
light blue line). Culture density indicated by absorbance (nm) on the y-axis and time (hrs) after -synuclein  induction. Data points representative of 
mean of three trials. Standard Error of the Mean (S.E.M.) bars given for each for each data point. No difference in growth observed between WT-GFP 
and A76E in fission yeast in -synuclein  inducing media. (n=3; p=241208). 
E. Cell Spotting: PP, GFP, WT-GFP and A76E -synuclein  expressing cells were serially diluted and spotted on -synuclein  inducing (EMM-thiamine) 
and suppressing (EMM+thiamine) media to evaluate effect of -synuclein  expression on cell growth. Media plate with -synuclein  repressing solid 
media EMM+thiamine to the left and media plate with -synuclein  inducing solid media EMM-thiamine to the right. No difference in growth observed 
between WT-GFP and A76E on -synuclein  inducing or suppressing media. 
 
Lack of Toxicity Observed for A76E Expressing Cells 
Lastly, we asked whether the decreased aggregation would 
alter -synuclein toxicity in fission yeast. OD600 growth 
curves demonstrated that A76E cells grew just as well as 
those containing parent vector, or expressing GFP alone or 
wildtype -synuclein (Figure 8D; p=.241208), indicating that 
decreased aggregation did not increase or decrease toxicity. 
Serial spotting confirmed a lack of A76E induced toxicity, as 
no difference in colony survival was observed between wild-
type and A76E--synuclein, and this level of colony survival 
was similar to that of cells containing parent vector or 
expressing GFP alone (Figure 8E). Collectively, both assays 
indicated that A76E does not induce toxicity in fission yeast 
cells. 
 
Discussion 
 
In most biological systems, despite the significant 
expenditure of energy to avoid the natural tendency of some 
proteins to aggregate and form harmful deposits, some 
proteins nonetheless misfold and aggregate. The misfolding, 
aggregation, and membrane phospholipid binding of -
synuclein is linked to both familial and sporadic forms of PD. 
This study provides strong relevance of alanine-76 to PD, by 
reporting that the substitution mutant A76E significantly 
reduces -synuclein aggregation in live cells, without 
increasing plasma membrane association, or conferring 
toxicity to fission yeast.  
 
The Contribution of Alanine-76 to Aggregation of -Synuclein 
Our first notable finding is that A76E reduces -synuclein 
aggregation in fission yeast, providing critical live cell 
support for the hypothesis that alanine-76 is an important 
regulator of -synuclein aggregation. Previously, in vitro 
studies had implicated alanine-76 within -synuclein as an 
intrinsic contributor to its aggregation and pathogenesis 
(Chiti et al., 2000; Gaisson et al., 2001). Through deletion 
analysis, Giasson et al (2001) identified a hydrophobic 
stretch of twelve amino acids (70-82) thought to be 
responsible for -synuclein aggregation. Both Giasson et al. 
(2000) and Chiti et al. (2001) pointed to alanine-76 as being 
the key amino acid within this stretch that contributed the 
hydrophobicity necessary for aggregation. Our finding 
provides new evidence to extend these studies, and 
indicates that in sporadic and familial PD, alanine-76 may be 
critically involved in misfolding and aggregation of -
synuclein.  
Because A76E replaces hydrophobicity with a 
negative charge, it should also reduce the ability of -
synuclein to associate with the plasma membrane.  In fact, 
we do not see a redistribution of -synuclein to the plasma 
membrane in fission yeast. Instead, it redistributes in the 
cytoplasm. Further evidence for reduced plasma membrane 
localization comes from our budding yeast model, where 
A76E reduces membrane localization, without any increase 
in aggregation (Michael Zorniak Thesis 2007; See appendix 
B, pg 62). In this model, not surprisingly, an increase in the 
number of live cells displaying a diffuse/halo phenotype 
correlated with the loss of membrane localization, indicative 
of a more hydrophilic -synuclein. Therefore, in both fission 
and budding yeast models, we observed a reduction in the 
amount of aggregation and membrane localization, indicative 
of the contribution of alanine-76 to the hydrophobic 
properties of -synuclein.  
 
Lack of A76E Induced Toxicity 
The second notable finding was that while A76E resulted in 
reduced -synuclein aggregation, it did not affect toxicity in 
fission yeast. Although reduced, aggregation is still observed 
in live cells, therefore, its’ possible that these remaining 
aggregates are protective rather than toxic (Rochet et al., 
2004), and thus prevents toxicity. Additionally, the lack of -
synuclein membrane localization may contribute to the 
absence of toxicity in A76E fission yeast cells. In support of 
this notion, our A76E budding yeast model demonstrates a 
reduced -synuclein membrane localization and yet is toxic 
(Michael Zorniak Thesis, 2007; See appendix, pg 63). We 
believe that this budding yeast toxicity is due to absence of 
visible aggregation and yet enough retention of membrane 
localization to be toxic to yeast. Thus, our budding and 
fission yeast data for A76E are consistent with E46K results, 
and provides general support for an emerging hypothesis in 
the PD field for -synuclein toxicity being linked to its 
association with plasma membranes.  
 
Chapter 3: Characterization of Post-translational 
Modification Mutations in Fission Yeast 
 
Results 
 
Post-translational Modification Mutants Maintain Aggregation 
Our first goal was to test the prediction that one or more of 
the nitrosylation-deficient (Y39A andY125F) and 
phosphorylation-deficient (S87A and S129A) mutants would 
reduce -synuclein aggregation in fission yeast cells. To this 
end, we evaluated the effect of post-translational mutations 
on -synuclein localization in fission yeast cells through live 
cell GFP microscopy (Figure 9A). As expected, over a time 
course, wild-type -synuclein aggregated by 24 hours and 
remained aggregated (Figure 9A-B). At 12 hours, however, 
the amount of aggregation of all four post-translational 
modification mutants was higher than wild-type -synuclein, 
contrary to our hypothesis (Figure 9A-B). But by 36 hours, 
aggregation levels between post-translational mutants and 
wild-type -synuclein were similar (Figure 9A-B). 
Interestingly, we observed a second intracellular localization 
pattern (“other”) for wild-type and all four mutant forms of -
synuclein; but the number of cells that exhibited this 
phenotype were fewer. This “other” phenotype was similar to 
the type we had observed in wild-type and E46K -synuclein 
in Chapter 1. 
 
 
 
 
Figure 9.  Characterization of Post-translationally Mutant -synuclein in Fission Yeast 
A. Live Cell Microscopy:  All fission yeast cell constructs C-terminally tagged with GFP. Fluorescent images of WT-GFP, S87A, S129A, Y39F, and 
Y125F -synuclein fission yeast taken over 36 hour time course at 1000X magnification. Images taken at 12, 24 and 36  hours post-induction. 
B. Quantification of Phenotypes: A total of 750 cells were imaged for quantification. At each time point, cells were quantified as having either aggregate 
fluorescence (dark blue), aggregate/ diffuse fluorescence (maroon), other (yellow). Percentage of cells exhibiting each phenotype at 12, 24, and 36 
hours plotted.  
C. Western blot Analysis: Cells were grown in -synuclein inducing (EMM-thiamine) media for 24 hours. At 24 hours, western analysis was performed. 
Blots were probed with an anti-V5 antibody, which binds exclusively to the V5 tag on -synuclein.  -synuclein bands are visible at ~52 kDa. There is 
no difference in expression between post-translational modification mutants and WT.  
D. Growth Curve Analysis: Growth Curve during 48 hours of expression for parent plasmid (blue), GFP ( pink), WT-GFP (yellow line), S87A (light blue 
line), S129A (purple), Y39F (brown line), and Y125F (green line). Culture density indicated by absorbance (nm) on the y-axis and time (hrs) after -
synuclein  induction on x-axis. Data points representative of mean of three trials. Standard Error of the Mean (S.E.M.) bars given for each for each data 
point. No major difference in growth observed between WT-GFP, S87A, S129A, Y39F, and Y125F fission yeast in -synuclein  inducing media. (n=3; 
S87A: p=.060802, S129A: p=.026591, Y39F: p=.040414, Y125F: p=.024439) 
E. Serial Spotting: WT-GFP, S87A, S129A, Y39F, and Y125F -synuclein  expressing cells were serially diluted and spotted on -synuclein  inducing 
(EMM-thiamine) and suppressing (EMM+thiamine) media to evaluate effect of -synuclein  expression on cell growth. Media plate with -synuclein  
repressing solid media EMM+thiamine to the left and media plate with -synuclein  inducing solid media EMM-thiamine to the right. No difference in 
growth observed between WT-GFP, S87A, S129A, Y39F, and Y125F on -synuclein  inducing or suppressing media. 
Post-translational Modification Mutants Maintain Size on 
Gels 
We performed Western blot analysis at 24 hours post-
induction in order to test the hypothesis that one of these 
four post-translational modifications was responsible for the 
abnormal migration (about 10 KDa higher) of -synuclein in 
yeast lysates. Interestingly, all four mutants maintained a 
migration size similar to wild-type -synuclein on SDS-PAGE 
gels (Figure 9C).  
 
Post-translational Modification Mutants Do Not Result in 
Major Toxicity 
Lastly, we evaluated the effects of these four -synuclein 
mutants on cellular toxicity, using optical density assay and 
serial spotting analysis. In fact, we observed slight difference 
in growth curves between parent vector, GFP alone, wild-
type -synuclein, and any of the four -synuclein mutants 
(Figure 9D). Despite significant toxicity, we do not consider 
this toxicity to be major (S87A: p=.060802, S129A: 
p=.026591, Y39F: p=.040414, Y125F: p=.024439).Nor did 
we observe any difference within all these strains, in their 
colony formation on serially diluted spotted plates (Figure 9 
E). Collectively, both assays demonstrate that post-
translational mutations do not regulate -synuclein toxicity in 
fission yeast. 
 
Discussion 
 
Several factors may contribute to the misfolding and 
aggregation of -synuclein and aid in the progression of PD. 
Among those suggested in PD literature, are specific 
posttranslational modifications on -synuclein, 
phosphorylation on serine-87 and serine-129, and 
nitrosylation on tyrosine-39 and tyrosine-125. Despite some 
supporting in vitro evidence, whether these modifications 
actually aid in PD pathogenesis or are harmless or even 
beneficial has not been resolved.  Our major finding here is 
that neither the phosphorylation-deficient mutants nor the 
nitrosylation-deficient mutants reduce -synuclein 
aggregation in fission yeast, nor do they affect toxicity. When 
combined with parallel studies done in a budding yeast 
model (Sara Herrera Thesis, 2005, See appendix C pg 65), 
our conclusion is that all of these post-translational 
modifications are, in fact, potentially beneficial to cells. 
 
Why Don’t Post-Translational Deficient Mutants Reduce 
Aggregation? 
The most notable finding is lack of reduction in aggregation 
of the four post-translational modification mutants. The 
simplest explanation could be that neither phosphorylation 
nor nitrosylation of -synuclein affect aggregate formation in 
vivo. What is the evidence that these modifications do 
enhance aggregation? In the case of phosphorylation, in 
vitro evidence suggests that (i) -synuclein is 
phosphorylated at serine-87 and serine-129 (Fujiwara et al., 
2002); (ii) this phosphorylation promotes the formation of 
fibrils in vitro (Fujiwara et al., 2002); and (iii) mutating 
phosphorylation sites decreases inclusion formation (Smith 
et al., 2005). However, other studies contest some of these 
findings. First, blocking phosphorylation of serine-129 
increases aggregate formation (Chen and Feany, 2005). 
Secondly, Lee et al (2004) find that S129A does not have 
any impact on inclusion formation.   
In the case of nitrosylation, in vitro evidence 
suggest that (i) -synuclein  is nitrosylated at tyrosine 39 and 
tyrosine-125 (Takahashi et al., 2002); (ii) an increase in the 
ratio of nitrating agent to results in the augmentation of -
synuclein aggregates (Paxinou et al., 2001) and -synuclein  
oligomers (Souza et al., 2000) and (iii) tyrosine-125 may play 
a critical role in -synuclein dimerization, as a lack of this 
residue significantly decreases dimerization compared to -
synuclein lacking tyrosine-39 (Takahashi et al.,2002). Our in 
vivo fission yeast evidence, however, does not correlate with 
in vitro evidence, our nitration and phosphorylation deficient 
mutants do not alter the aggregation rates of the protein. 
Interestingly, in parallel studies in budding yeast (Sara 
Herrera Thesis, 2005; See appendix C, pg 64), none of 
these mutants affected aggregation. Instead, all of them 
maintain plasma membrane localization.  A second 
explanation for lack of aggregations differences due to post-
translation modification could be that such modifications do 
not happen in yeast. It is important to note that we have not 
tested for either -synuclein phosphorylation or nitrosylation 
in our yeast model. Furthermore, it is possible that more than 
one post-translational modification is necessary to alter rate 
of -synuclein aggregation.  
 
Why Don’t Post-Translational Modification-Deficient Mutants 
Reduce Toxicity? 
Our second notable finding is that all four mutants lack major 
toxicity in fission yeast. A simple reason could be that the 
post-translational modification mutants retained high levels 
of aggregation comparable to wild-type. As previously 
discussed in chapters I and II, these aggregates may be 
protective, so the presence of aggregation may lead to the 
lack of toxicity seen observed in these mutants, as well as 
wild-type, A53T, A76E, E46K. Secondly, these mutants do 
not localize to the plasma membrane in fission yeast, which 
may have been a key factor to generate toxicity. We know 
from the budding yeast model, where significant toxicity was 
observed with four all mutants, a significant amount of 
membrane localization existed (Sara Herrera, 2005; See 
Appendix C, pg 61). Most interestingly, a recent study using 
a rat model of PD demonstrates that S129A accelerates 
neurodegeneration, while constitutive phosphorylation of 
serine 129 protects against neurodegeneration (Gorbatyuk 
et al., 2008). 
Understanding a possible mechanism for neuron 
protection in mice may be important for the possibility of 
therapeutic treatment. Furthermore, understanding the 
protective mechanisms that fission yeast may have to 
protect it from the phosphorylation-deficiency dependent 
toxicity observed in other models may also help us 
understand the mechanism of neurodegeneration.  
 
Why Don’t Post-Translational Modification-Deficient Mutants 
Migrate More Quickly?  
We tested the hypothesis that these post-translational 
mutations were responsible for the aberrant size (~10 kDa 
higher) of -synuclein. Interestingly, fission yeast post-
translational modification mutants, like budding yeast post-
translational modification mutants (Sara Herrera thesis, 
2005; See appendix C, pg 61), do not influence the size 
change of -synuclein. A possibility exists that these 
modifications, if these occur at all, are not responsible for the 
aberrant size of -synuclein. Furthermore, it is possible that 
other post-translational modifications such as glycosylation 
and ubiquitination (Shimura et al., 2001), or a combination of 
modifications could result in the increased size of -
synuclein. Lastly, the higher migration of -synuclein could 
be due to other factors, such as the possible change in 
conformation of the protein.  Adopting a specific 
conformation could result in the decreased motility of the 
protein through the gel, however, little is known about the 
specific conformational changes that may result in the 
increased size of -synuclein.  
 
Conclusion 
 
This thesis examined several hypotheses that focused 
primarily focused on the aggregation and phospholipid 
binding properties of -synuclein and how one or both are 
linked to cellular toxicity. Our findings provide new and 
converging insights into the pathogenesis that underlies both 
forms of PD, sporadic and familial. In our first study, we 
found that E46K, the newest familial -synuclein mutant, 
aggregates extensively in fission yeast, as we had 
hypothesized. Contrary to our prediction, however, E46K -
synuclein does not aggregate faster that wild-type -
synuclein and lacks plasma membrane localization. In our 
second study, we found that the -synuclein mutant A76E 
reduces the rate of -synuclein aggregation, supporting our 
hypothesis that alanine-76 is a key contributor to -
synuclein’s aggregation propensity. In our final study, we 
found that phosphorylation and nitrosylation deficient -
synuclein mutants maintain both aggregation and do not 
affect toxicity, contrary to our hypothesis that such post-
translational modifications of -synuclein facilitate its 
aggregation and possibly confer toxicity. Interestingly, we 
also found that post-translational modification mutants did 
not change the size of -synuclein, implicating other factors 
in the aberrant migration of -synuclein in yeast models.   
 Together, these three studies point to key amino 
acid residues within -synuclein that control their 
aggregation status. This thesis also further confirms fission 
yeast as a model organism that is particularly resistant to -
synuclein toxicity. For this reason, it is  an attractive system 
in which to identify novel factors that provide such protection. 
 
Budding and Fission Models: Both Powerful Tools for -
synuclein Characterization 
While several differences have emerged in the 
characterization -synuclein properties in budding and 
fission yeast, these differences stress the usefulness of 
using both models in the examination of -synuclein 
misfolding and aggregation. Fission yeast is excellent for 
understanding the basis for aggregation of -synuclein, while 
budding yeast serves as an effective model -synuclein 
membrane phospholipid localization. Together, both yeast 
models provide a more complete assessment of factors 
necessary for cellular toxicity. The differences in -synuclein 
properties between the two yeasts may be due to differences 
in their genomes, or to differences in their expressed prote 
omes.  
 
Limitations 
We do not know the nature of the aggregates that form in 
fission yeast and whether they are truly cytoplasmic or linked 
to specific cytoplasmic structures/organelles. Using 
organelle specific markers or dyes may provide clarity. A 
second major limitation is that the quantification examined 
using GFP microscopy is a non-blind process. A possibility 
exists that this process could result in slight variations of 
results if performed by different people. Lastly, while 
effective, our unicellular model does not allow us to examine 
the physical manifestations of the disease that are observed 
in other models.  
 
Future Studies 
Future studies will include the characterization of 
combination mutants of E46K and the two other familial 
mutants A30P and A53T to assess the contribution of one 
mutant over the other in controlling aggregation. Similarly, 
we will conduct experiments with combination mutants of 
more than post-translational modifications, since single 
mutants did influence toxicity or reduce -synuclein 
migration size. Fuller characterization of these -synuclein 
mutants may increase our understanding of not only -
synuclein function, but also the mechanisms of its 
aggregation and cellular toxicity, which may potentially help 
us in developing treatment for PD. 
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